Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease
NCT03395184
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
1. Male and/or female subjects 18 years to 75 years of age
2. Documented diagnosis of ileal, ileocolonic, or colonic CD with a minimum disease duration of 3 months, as determined by endoscopic and histopathology assessment.
3. Endoscopic confirmation of active disease with total SES CD total score of at least 7. For isolated ileal disease, SES CD total score should be at least 4.
4. An average daily liquid/soft stool frequency (SF) greater than or equal to 2.5 or daily abdominal pain (AP) greater than or equal to 2.0.
5. Must have inadequate response to, loss of response to, or intolerance to at least one conventional therapy for CD:
•Steroids; Immunosuppressants (azathioprine [AZA], 6 MP, or methotrexate [MTX]); Anti TNF inhibitors (infliximab, adalimumab,certolizumab); Anti integrin inhibitors (eg, vedolizumab); Anti IL 12/23 inhibitor (ustekinumab).
6. Subjects currently receiving the following treatment for CD are eligible providing they have been on stable doses as described below:
- Oral corticosteroids (prednisone or equivalent up to 25 mg/day; budesonide up to 9 mg/day). Stable dose for at least 2 weeks prior to baseline. If oral corticosteroids have been recently discontinued, they must have been stopped at least 2 weeks prior to baseline. Decreases in steroid use due to AEs are allowed.
- Oral 5 ASA or sulfasalazine are allowed providing that the dose is stable for at least 4 weeks prior to baseline.
- Crohn's disease related antibiotics are allowed providing that the dose is stable for at least 4 weeks prior to baseline. If antibiotics are stopped prior to baseline, they must be discontinued at least 4 days prior to baseline.
1. Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, infectious
colitis, radiation colitis, diverticular disease, ulcerative colitis (UC), or clinical
findings suggestive of UC.
2. Presence of active (draining) fistulae or intra abdominal or perineal abscesses.
3. Strictures with obstructive symptoms.
4. Short bowel syndrome.
5. History of bowel perforation requiring surgical intervention within the past 12
months.
6. Previous bowel surgery resulting in an existing stoma. Subjects who have a j pouch are
excluded, as a j pouch can result in a stoma.
7. History of bowel surgery within 6 months prior to baseline.
8. Subjects displaying clinical signs of fulminant colitis or toxic megacolon.
9. Subjects with primary sclerosing cholangitis.
10. Subjects with evidence of colonic adenomas, dysplasia or neoplasia.
11. Abnormal findings on the chest x ray film such as presence of tuberculosis (TB),
general infections, heart failure, or malignancy.
12. Any history of either untreated or inadequately treated latent or active TB infection,
current treatment for active or latent TB infection or evidence of currently active TB
by chest x ray, residing with or frequent close contact with individual(s) with active
TB.
13. Subjects receiving the following therapies within the time period described below or
expected to receive any of these therapies during the study period:
1. >9 mg/day of oral budesonide or >25 mg/day of prednisone or equivalent oral
systemic corticosteroid dose within 2 weeks prior to baseline.
2. IV, IM (parenteral), or topical (rectal) treatment of 5 ASA or corticosteroid
enemas/suppositories within 2 weeks prior to baseline.
3. Azathioprine, 6 mercaptopurine, or methotrexate within 2 weeks prior to baseline.
4. Anti TNF inhibitors (or biosimilars thereof) as described below:
- Infliximab within 8 weeks prior to baseline;
- Adalimumab within 8 weeks prior to baseline;
- Certolizumab within 8 weeks prior to baseline;
5. Anti integrin inhibitors (eg, vedolizumab) within 8 weeks prior to baseline.
6. Ustekinumab within 8 weeks prior to baseline.
7. Interferon therapy within 8 weeks prior to baseline.
8. Subjects with prior treatment with lymphocyte depleting agents/therapies within 1
year prior to baseline (eg, CamPath[alemtuzumab], alkylating agents [eg,
cyclophosphamide or chlorambucil], total lymphoid irradiation, etc).
9. Subjects who have received rituximab or other selective B lymphocyte depleting
agents within 1 year prior to baseline.
10. Subjects previously receiving leukocyte apheresis, including selective
lymphocyte, monocyte, or granulocyte apheresis, or plasma exchange within 6
months prior to baseline.
11. Other marketed immunosuppressants or biologics with immunomodulatory properties
within 3 months prior to baseline.
12. Subjects who have received other JAK inhibitors within 3 months prior to
baseline.
13. Subjects who have not responded to or have been intolerant of other JAK
inhibitors.
14. Other investigational procedures(s) or product(s), such as immunosuppressants
used in transplantation (eg, mycophenolate mofetil, cyclosporine, rapamycin, or
tacrolimus) or live (attenuated) vaccine within 30 days prior to baseline.
14) Subjects with history of thrombotic event(s), including deep venous
thrombosis (DVT), and known inherited conditions that predispose to
hypercoagulability.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Nashville, Tennessee
- Brussels,
- Leuven,
- Helsinki,
- Rotterdam, Zuid-Holland
- Amsterdam,
- Amsterdam,
- Breda,
- Enschede,
- Leiden,
- Nijmegen,
- Rotterdam,
- Utrecht,
- Zwolle,
- Scottsdale, Arizona
- Scottsdale, Arizona
- Tucson, Arizona
- Tuscon, Arizona
- Lakewood, Colorado
- Littleton, Colorado
- Wheat Ridge, Colorado
- Wheatridge, Colorado
- Hamden, Connecticut
- Clearwater, Florida
- Clearwater, Florida
- Crystal River, Florida
- Inverness, Florida
- Inverness, Florida
- Sanford, Florida
- Decatur, Georgia
- Decatur, Georgia
- Marietta, Georgia
- Arlington Heights, Illinois
- Chicago, Illinois
- Evanston, Illinois
- Lexington, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Annapolis, Maryland
- Annapolis, Maryland
- Grand Rapids, Michigan
- Wyoming, Michigan
- Wyoming, Michigan
- Wyoming, Michigan
- Ypsilanti, Michigan
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Oklahoma, Oklahoma
- Tulsa, Oklahoma
- Tulsa, Oklahoma
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Germantown, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Austin, Texas
- Austin, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- Southlake, Texas
- Tyler, Texas
- Tyler, Texas
- Salt Lake City, Utah
- Richmond, Virginia
- Richmond, Virginia
- Concord, New South Wales
- Brisbane, Queensland
- South Brisbane, Queensland
- Box Hill, Victoria
- Clayton, Victoria
- Fitzroy, Victoria
- Bruxelles,
- Bruxelles,
- Leuven,
- Roeselare,
- Curitiba, PR
- Curitiba, PR
- Curitiba, PR
- Rio de Janeiro, RJ
- Rio de Janeiro, RJ
- São Paulo, SP
- Calgary, Alberta
- London, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Hradec Kralove,
- Olomouc,
- Praha 10,
- Praha 4,
- Usti nad Labem,
- Aarhus C,
- Herlev,
- Hilleroed,
- Hvidovre,
- Koebenhavn NV,
- Koebenhavn,
- Koege,
- Paris, Cedex 12
- Lille Cedex,
- Hannover, Niedersachsen
- Hamburg,
- Kiel,
- Minden,
- Budapest,
- Debrecen,
- Szeged,
- Szekszard,
- Dublin,
- Dublin,
- Dublin,
- Dublin,
- Galway,
- Beith Vagan, Jerusalem
- Haifa,
- Jerusalem,
- Kfar Saba,
- Petah Tikva,
- Tel Aviv,
- Rozzano, Milano
- Padova,
- Roma,
- Rome,
- Milford, Auckland
- Hamilton,
- Zuerich,
- Cambridge,
- Glasgow,
- London,
- London,
- London,
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease | ||||||
Official Title ICMJE | A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN'S DISEASE | ||||||
Brief Summary | The objectives of this study are to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06651600 (200 mg for 8 weeks followed by 50 mg for 4 weeks) dosed once daily and PF-06700841 (60 mg for 12 weeks) dosed once daily during an induction period of 12 weeks, followed by an open label extension period at doses of 50 mg and 30 mg of PF 06651600 and PF 06700841, respectively, for 52 weeks. | ||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 2 | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment | ||||||
Condition ICMJE | Crohn's Disease | ||||||
Intervention ICMJE |
| ||||||
Study Arms ICMJE |
| ||||||
Publications * | Fensome A, Ambler CM, Arnold E, Banker ME, Brown MF, Chrencik J, Clark JD, Dowty ME, Efremov IV, Flick A, Gerstenberger BS, Gopalsamy A, Hayward MM, Hegen M, Hollingshead BD, Jussif J, Knafels JD, Limburg DC, Lin D, Lin TH, Pierce BS, Saiah E, Sharma R, Symanowicz PT, Telliez JB, Trujillo JI, Vajdos FF, Vincent F, Wan ZK, Xing L, Yang X, Yang X, Zhang L. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). J Med Chem. 2018 Oct 11;61(19):8597-8612. doi: 10.1021/acs.jmedchem.8b00917. Epub 2018 Aug 16. | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Recruiting | ||||||
Estimated Enrollment ICMJE | 250 | ||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||
Estimated Study Completion Date ICMJE | November 30, 2022 | ||||||
Estimated Primary Completion Date | November 30, 2022 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 18 Years to 75 Years (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE |
| ||||||
Listed Location Countries ICMJE | Australia, Austria, Belgium, Bosnia and Herzegovina, Canada, Croatia, Czechia, Georgia, Germany, Hungary, Italy, Korea, Republic of, Lebanon, Poland, Russian Federation, Saudi Arabia, Serbia, Slovakia, South Africa, Spain, Switzerland, Tunisia, Turkey, Ukraine, United Arab Emirates, United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT03395184 | ||||||
Other Study ID Numbers ICMJE | B7981007 2017-003359-43 ( EudraCT Number ) PIZZICATO ( Other Identifier: Alias Study Number ) | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
| ||||||
IPD Sharing Statement ICMJE |
| ||||||
Responsible Party | Pfizer | ||||||
Study Sponsor ICMJE | Pfizer | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
| ||||||
PRS Account | Pfizer | ||||||
Verification Date | January 2021 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |